Literature DB >> 16940774

Motor impulsivity in APP-SWE mice: a model of Alzheimer's disease.

Walter Adriani1, Elisa Ognibene, Emilie Heuland, Orlando Ghirardi, Antonio Caprioli, Giovanni Laviola.   

Abstract

Among transgenic mouse models of Alzheimer's disease, APP-SWE mice have been shown to develop beta-amyloid plaques and to exhibit progressive impairment of cognitive function. Human Alzheimer's disease, however, also includes secondary clinical manifestations, spanning from hyperactivity to agitation. The aim of this study was a better characterization of motor impulsivity in APP-SWE mice, observed at 12 months of age, when levels of soluble beta-amyloid are elevated and beta-amyloid neuritic plaques start to appear. Mice were tested for spatial learning abilities in the Morris water maze (seven daily sessions, four trials per day). The distance traveled to reach the hidden platform showed a learning curve in both groups. This profile, however, was somewhat delayed in APP-SWE mice, thus confirming slightly impaired spatial capacities. To evaluate motor impulsivity, animals were trained to nose-poke for a food reward, which was delivered after a waiting interval that increased over days (15-60 s). Further nose-poking during this signaled waiting interval resulted in food-reward loss and electric-shock punishment. APP-SWE mice received an increased quantity of punishment and were able to earn fewer food rewards, suggesting inability to wait already at the lowest delay. After the animals were killed, prefrontal cortex samples were assessed for neurochemical parameters. Serotonin turnover was elevated in the prefrontal cortex of APP-SWE mice compared with controls. The results clearly confirm cognitive deficits, and are consistent with the hypothesis of reduced behavioral-inhibition abilities. Together with recent findings, APP-SWE mice emerge as a suitable animal model, characterized by a number of specific behavioral alterations, resembling primary and secondary symptoms of human Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940774     DOI: 10.1097/00008877-200609000-00019

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  5 in total

1.  A novel operant testing regimen for multi-construct cognitive characterization of a murine model of Alzheimer's amyloid-related behavioral impairment.

Authors:  Alice L Blackshear; Wenjin Xu; Maria Anderson; Feng Xu; Mary Lou Previti; William E Van Nostrand; John K Robinson
Journal:  Neurobiol Learn Mem       Date:  2011-07-08       Impact factor: 2.877

2.  Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008).

Authors:  Dave Morgan; Marcia N Gordon
Journal:  Behav Neurosci       Date:  2008-06       Impact factor: 1.912

3.  DNA damage and cell cycle events implicate cerebellar dentate nucleus neurons as targets of Alzheimer's disease.

Authors:  Jianmin Chen; Mark L Cohen; Alan J Lerner; Yan Yang; Karl Herrup
Journal:  Mol Neurodegener       Date:  2010-12-20       Impact factor: 14.195

4.  Limited effects of an eIF2αS51A allele on neurological impairments in the 5xFAD mouse model of Alzheimer's disease.

Authors:  Katharina Paesler; Kan Xie; Moritz M Hettich; Magdalena E Siwek; Devon P Ryan; Susanne Schröder; Anna Papazoglou; Karl Broich; Ralf Müller; Astrid Trog; Alexander Garthe; Gerd Kempermann; Marco Weiergräber; Dan Ehninger
Journal:  Neural Plast       Date:  2015-03-26       Impact factor: 3.599

5.  The reemergence of long-term potentiation in aged Alzheimer's disease mouse model.

Authors:  Seonghoo Huh; Soo-Ji Baek; Kyung-Hwa Lee; Daniel J Whitcomb; Jihoon Jo; Seong-Min Choi; Dong Hyun Kim; Man-Seok Park; Kun Ho Lee; Byeong C Kim
Journal:  Sci Rep       Date:  2016-07-05       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.